Quarterly report pursuant to Section 13 or 15(d)

Segment Reporting - Schedule of Segment Information (Details)

v3.19.3
Segment Reporting - Schedule of Segment Information (Details) - USD ($)
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Net revenues - External $ 5,190,650 $ 1,601,661  
Net loss from continuing operations before income taxes (12,932,795) (146,786,301)  
Depreciation and amortization 223,586 333,515  
Capital expenditures 42,317 301  
Total assets 15,612,735   $ 14,199,300
Hospital Operations [Member]      
Net revenues - External 5,105,265 1,556,075  
Net loss from continuing operations before income taxes (3,175,107) (1,472,600)  
Depreciation and amortization 173,776 37,728  
Capital expenditures 42,317 301  
Total assets 14,856,310   13,568,933
Clinical Laboratory Operations [Member]      
Net revenues - External 85,385 45,586  
Net loss from continuing operations before income taxes (225,530) (756,083)  
Depreciation and amortization 49,662 295,474  
Capital expenditures  
Total assets 462,354   271,426
Corporate [Member]      
Net loss from continuing operations before income taxes (1,072,835) (1,483,341)  
Depreciation and amortization 148 313  
Total assets 2,588,391   2,707,416
Other Income Expense Net [Member]      
Net loss from continuing operations before income taxes (8,459,323) $ (143,074,277)  
Assets of AMSG And HTS Classified as Held for Sale [Member]      
Total assets 172,539   152,171
Eliminations [Member]      
Total assets $ (2,466,859)   $ (2,500,646)